189 related articles for article (PubMed ID: 31625001)
1. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice.
Legué LM; Bernards N; Lemmens VE; de Hingh IH; Creemers GJ; van Erning FN
United European Gastroenterol J; 2019 Dec; 7(10):1380-1388. PubMed ID: 31839964
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
4. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Horimatsu T; Nakayama N; Moriwaki T; Hirashima Y; Fujita M; Asayama M; Moriyama I; Nakashima K; Baba E; Kitamura H; Tamura T; Hosokawa A; Yoshimura K; Muto M
Int J Clin Oncol; 2017 Oct; 22(5):905-912. PubMed ID: 28536826
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
Aydin D; Sendur MA; Kefeli U; Ustaalioglu BB; Aydin O; Yildirim E; Isik D; Ozcelik M; Surmeli H; Oyman A; Isik S; Sener N; Ercelep O; Odabas H; Aliustaoglu M; Gumus M
Clin Colorectal Cancer; 2017 Mar; 16(1):78-83. PubMed ID: 27247089
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH
J BUON; 2011; 16(4):689-96. PubMed ID: 22331723
[TBL] [Abstract][Full Text] [Related]
8. Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Berk V; Deniz K; Bozkurt O; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(14):6149-54. PubMed ID: 26320510
[TBL] [Abstract][Full Text] [Related]
9. Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Payette E; Sarker S; Chalchal H
Can J Rural Med; 2017; 22(4):148-152. PubMed ID: 28925914
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma.
Amano T; Iijima H; Shinzaki S; Tashiro T; Iwatani S; Tani M; Otake Y; Yoshihara T; Sugimoto A; Egawa S; Yamaguchi S; Kinoshita K; Araki M; Hirao M; Sakakibara Y; Hiyama S; Ogawa H; Nagaike K; Murata J; Komori M; Okuda Y; Kizu T; Tsujii Y; Hayashi Y; Inoue T; Takahashi H; Mizushima T; Morii E; Takehara T
BMC Cancer; 2021 Aug; 21(1):978. PubMed ID: 34465291
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
Overman MJ; Kopetz S; Wen S; Hoff PM; Fogelman D; Morris J; Abbruzzese JL; Ajani JA; Wolff RA
Cancer; 2008 Oct; 113(8):2038-45. PubMed ID: 18759326
[TBL] [Abstract][Full Text] [Related]
12. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
13. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
[TBL] [Abstract][Full Text] [Related]
14. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J
Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806
[TBL] [Abstract][Full Text] [Related]
17. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study.
Razenberg LG; van Gestel YR; Lemmens VE; de Hingh IH; Creemers GJ
Clin Colorectal Cancer; 2016 Jun; 15(2):e41-6. PubMed ID: 26762572
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
